Özgen Ahmet Yıldırım

10PUBLICATIONS
24CO-AUTHORS
PharmacogenomicsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Allergy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Oct 27, 2026
The Role of Dominant Lesion Site and SUVmax in the Depth of PSA Response in Metastatic Hormone-Sensitive Prostate Cancer.

|Sep 15, 2026
Claudin 18.2 Positivity Thresholds and Candidate Populations for Targeted Therapy in Pancreatic Ductal Adenocarcinoma: A Real-World Retrospective Cohort.

|Jul 28, 2026
Proton Pump Inhibitor Use and Survival Outcomes in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Immunotherapy: A Real-World Study.

|May 27, 2026
Exploring the impacts of docetaxel and paclitaxel based neoadjuvant therapies on early postoperative complications in HER2-positive breast cancer patients.

|May 04, 2026
Clinicopathological Predictors of Pathological Complete Response in HER2-Positive Breast Cancer Treated with Pertuzumab-Based Neoadjuvant Therapy: A Multicenter Real-World Study.

|Oct 15, 2025
CALLY index as an independent predictor of pathological complete response in HER2-positive breast cancer receiving neoadjuvant therapy.

Salih Karatlı, Özgen Ahmet Yıldırım

Pageof 2

Frequent Collaborators

4 joint publications

Aysegül Ilhan Gülesen

4 joint publications

Salih Karatlı

3 joint publications

Kerem Poyraz

3 joint publications

Erkan Erdur